FDA Approves New Use for Xyzal: Allergic Rhinitis and Chronic Idiopathic Urticaria
According to a press release from the drug company: UCB and sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for Xyzal (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine used to relieve symptoms associated with indoor and outdoor allergies, as... Read more



